Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DREAMS

Financiado

Cerrado

Drug REpurposing with Artificial intelligence for Muscular disorderS

According to World Health Organization, to date, fewer than 6% of rare diseases (RDs) have an approved treatment option. In the light of this observation, it appears crucial to develop disruptive approaches that allow to find trea... ver más

31/10/2028

CECS

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

CENTRE DETUDE DES CELLULES SOUCHES No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-08

HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the nex... Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one o...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

CECS

1.67M€ | Lider

INSERM

895.00K€ | Participante

ZABALA

400.00K€ | Participante

SAMSARA THERAPEUTICS LTD

N.D. | Participante

Proyectos interesantes

REPO4EU

Medical Technol...

Data Science

23M€ Financiado

DISEASEAVATARS

Medical Technol...

Data Science

2M€ Cerrado

SIMPATHIC

Medical Technol...

Data Science

9M€ Financiado

BIOXPLOR

Medical Technol...

Data Science

71K€ Cerrado

MiniOrgans

Medical Technol...

Data Science

150K€ Financiado

ORGESTRA

Medical Technol...

Data Science

3M€ Financiado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2023-10-08
Fecha Fin: 2028-10-31

Líder del proyecto

CENTRE DETUDE DES CELLULES SOUCHES No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto According to World Health Organization, to date, fewer than 6% of rare diseases (RDs) have an approved treatment option. In the light of this observation, it appears crucial to develop disruptive approaches that allow to find treatments for multiple RDs. To achieve this goal, DREAMS will start from 5 rare neuromuscular disorders (NMD) that share common pathophysiological characteristics related to dysfunctions of autophagy and desmin disorganization. Using skeletal muscle cells derived from induced pluripotent stem cells (skMC-iPSC), DREAMS will i) identify shared biomarkers of the 5 diseases and ii) perform a high throughput drug screen on all 5 diseases. Through a first Artificial Intelligence (AI) based solution, the output of the drug screening will be used to find drug targets shared between the diseases. A second AI based solution will be used to find drug candidates (repurposable drugs and new molecular entities) for these shared drug targets. A third AI-based solution will be used to find additional diseases that could be treated through the shared drug targets, in order to extend the indications for the most promising drug candidates. Following their discoveries, the promising drug candidates will be tested for efficacy and safety in both iPSC and mouse models of the 5 NMDs and additional diseases. In parallel, DREAMS will design an adaptive clinical trial to prepare the final stages of drug development of these novel drug candidates with multiple indications. Together, these technological and conceptual innovations will allow the DREAMS consortium to i) develop therapies to treat multiple NMDs and related diseases, ii) to create a novel clinical design that generates a regulatory pathway for drugs that treat heterogeneous groups of patients suffering from RDs iii) to further the scientific understanding of commonalities in RDs, and iv) to create a reusable drug development platform to discover safe and effective treatments for RDs in general.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores